Journal of Liver Cancer最新文献

{"title":"Recent updates on the classification of hepatoblastoma according to the International Pediatric Liver Tumors Consensus.","authors":"Se Un Jeong,&nbsp;Hyo Jeong Kang","doi":"10.17998/jlc.2022.02.24","DOIUrl":"https://doi.org/10.17998/jlc.2022.02.24","url":null,"abstract":"<p><p>Hepatoblastoma is the most common pediatric liver malignancy and usually occurs within the first 3 years of life. In recent years, the overall incidence of hepatoblastoma has exhibited the greatest increase among all pediatric malignancies worldwide. The diagnosis of hepatoblastoma may be challenging due to the lack of a current consensus classification system. The International Pediatric Liver Tumors Consensus introduced guidelines and a consensus classification for the diagnosis of hepatoblastoma as either epithelial or mixed epithelial and mesenchymal and in the updated 5th edition of the World Health Organization Classification of Digestive System Tumors.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 1","pages":"23-29"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/c0/jlc-2022-02-24.PMC10035708.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10096404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term survival after CCRT and HAIC followed by ALPPS for hepatocellular carcinoma with portal vein invasion: a case report.","authors":"In-Jung Kim,&nbsp;Sung Hwan Yoo,&nbsp;Jung Il Lee,&nbsp;Kwan Sik Lee,&nbsp;Hyun Woong Lee,&nbsp;Jin Hong Lim","doi":"10.17998/jlc.2022.03.07","DOIUrl":"https://doi.org/10.17998/jlc.2022.03.07","url":null,"abstract":"<p><p>There are various methods for treating advanced hepatocellular carcinoma with portal vein invasion, such as systemic chemotherapy, transarterial chemoembolization, transarterial radioembolization, and concurrent chemoradiotherapy. These methods have similar clinical efficacy but are designed with a palliative aim. Herein, we report a case that experienced complete remission through \"associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)\" after concurrent chemoradiotherapy and hepatic artery infusion chemotherapy. In this patient, concurrent chemoradiotherapy and hepatic artery infusion chemotherapy induced substantial tumor shrinkage, and hypertrophy of the nontumor liver was sufficiently induced by portal vein ligation (stage 1 surgery) followed by curative resection (stage 2 surgery). Using this approach, long-term survival with no evidence of recurrence was achieved at 16 months. Therefore, the optimal use of ALPPS requires sufficient consideration in cases of significant hepatocellular carcinoma shrinkage for curative purposes.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 1","pages":"84-90"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/53/3a/jlc-2022-03-07.PMC10035705.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9791952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrent transarterial radioembolization and combination atezolizumab/bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report.","authors":"Min Kyung Park,&nbsp;Su Jong Yu","doi":"10.17998/jlc.2022.03.09","DOIUrl":"https://doi.org/10.17998/jlc.2022.03.09","url":null,"abstract":"<p><p>Treatment options for advanced hepatocellular carcinoma (HCC) have been rapidly evolving. Herein, we describe a patient with advanced HCC and portal vein tumor thrombosis (PVTT) who responded decisively to a multidisciplinary approach. The patient had an ill-defined infiltrative HCC (diffuse subtype), with several intrahepatic metastasis and tumor invasion of left portal vein. Concurrent use of transarterial radioembolization (TARE) and systemic therapeutics (atezolizumab + bevacizumab) ultimately proved successful. There was marked reduction in tumor volume after TARE and an additional three cycles of atezolizumab plus bevacizumab. This concurrent treatment was well tolerated, without adverse events during immunotherapy. The impressive results achieved suggest that concurrent TARE and combination atezolizumab/bevacizumab is a promising treatment approach for advanced HCC with PVTT.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 1","pages":"69-74"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/42/27/jlc-2022-03-09.PMC10035716.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10096402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sorafenib combined with radiation therapy for advanced hepatocellular carcinoma with portal and hepatic vein invasion extending to the inferior vena cava: a complete response case according to modified RECIST criteria.","authors":"Yuri Cho,&nbsp;Bo Hyun Kim,&nbsp;Tae Hyun Kim,&nbsp;Young Hwan Koh,&nbsp;Joong-Won Park","doi":"10.17998/jlc.2022.01.18","DOIUrl":"https://doi.org/10.17998/jlc.2022.01.18","url":null,"abstract":"<p><p>The prognosis of patients with advanced hepatocellular carcinoma (HCC) with tumor thrombus extending to the inferior vena cava (IVC) is extremely poor. Herein, we present a rare case of advanced HCC that was treated with sorafenib and radiotherapy, leading to complete remission. This patient had a 9 cm infiltrative HCC occupying almost the entire left lobe with a tumor thrombus extending through the hepatic vein, IVC, and left portal vein. The patient received 400 mg sorafenib twice daily. One year after the start of sorafenib, intensity-modulated radiation therapy for viable HCC and tumor thrombus was performed with a dose of 5,500 cGy. Twenty-seven months after the starting date of sorafenib, there was no intratumoral arterial enhancement, which suggested a complete response according to the modified RECIST criteria. This case suggests that the combination of sorafenib and radiotherapy might provide clinical benefits in patients with advanced HCC with IVC tumor thrombus.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 1","pages":"63-68"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/48/cf/jlc-2022-01-18.PMC10035710.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9791951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case report of advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy and sorafenib combination therapy followed by metastasectomy of lung and muscle metastases.","authors":"Sang Yi Moon, Sang Young Han, Yang-Hyun Baek","doi":"10.17998/jlc.2021.12.20","DOIUrl":"10.17998/jlc.2021.12.20","url":null,"abstract":"<p><p>Currently, various tyrosine kinase inhibitors and immune checkpoint inhibitors have been suggested in the treatment guidelines for advanced hepatocellular carcinoma (HCC). However, sorafenib was the only systemic drug approved 10 years ago. In 2010, a woman diagnosed with HCC rupture and multiple lung metastases visited our hospital. At the time of visiting our hospital, she had undergone transarterial chemoembolization at another hospital to control bleeding due to HCC rupture. We treated her with hepatic arterial infusion chemotherapy and sorafenib combination therapy to increase the control of intrahepatic tumors in consideration of the modest efficacy of sorafenib. The intrahepatic tumor was almost controlled. Metastasectomy was performed to control lung oligometastasis. Subsequently, additional muscle metastasis was confirmed, and metastasectomy was performed. Although this is a very rare case, it shows that a multidisciplinary approach can improve the prognosis of patients with HCC.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 1","pages":"57-62"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/de/f5/jlc-2021-12-20.PMC10035714.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10112956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in immune checkpoint inhibitors for hepatocellular carcinoma.","authors":"Ji Won Han,&nbsp;Su-Hyung Park","doi":"10.17998/jlc.2021.09.24","DOIUrl":"https://doi.org/10.17998/jlc.2021.09.24","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is the fifth most common cancer, and the second leading cause of cancer-related death worldwide. Although recent advances in immune checkpoint inhibitor-based immunotherapy have initiated a new era for advanced HCC treatment, the majority of HCC patients receiving immune checkpoint blockades do not derive clinical benefit. Thus, there remains an urgent need for novel immunotherapeutic strategies with improved therapeutic efficacy. Here we review recent studies of immune checkpoint blockade in HCC, providing the necessary basis for the rational design of immunotherapy.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"21 2","pages":"139-145"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/74/de/jlc-2021-09-24.PMC10035682.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9736719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in radiotherapy application according to regional disease characteristics of hepatocellular carcinoma.","authors":"Chai Hong Rim","doi":"10.17998/jlc.2021.05.26","DOIUrl":"10.17998/jlc.2021.05.26","url":null,"abstract":"<p><p>There are differences in opinion regarding the application of external beam radiotherapy in the treatment of hepatocellular carcinoma. Some major guidelines state that external beam radiotherapy is yet to attain a sufficient level of evidence. However, caution should be exercised when attempting to understand the clinical need for external beam radiotherapy solely based on the level of evidence. Previously, external beam radiotherapy had low applicability in the treatment of hepatocellular carcinoma before computed tomography-based planning was popularized. Modern external beam radiotherapy can selectively target tumor cells while sparing normal liver tissues. Recent technologies such as stereotactic body radiotherapy have enabled more precise treatment. The characteristics of hepatocellular carcinoma differ significantly according to the regional etiology. The main cause of hepatocellular carcinoma is the hepatitis B virus. It is commonly diagnosed as a locally advanced tumor but with relatively preserved hepatic function. The majority of these hepatocellular carcinoma cases are found in the East Asian population. Hepatocellular carcinoma caused by hepatitis C virus or other benign hepatitis tends to be diagnosed as a less locally aggressive tumor but with deteriorated liver function. The western world and Japan tend to have patients with such causes. External beam radiotherapy has been more commonly performed for the former, although the use of external beam radiotherapy in the latter might have more concerns with regard to hepatic toxicity. This review discusses the above subjects along with perspectives regarding external beam radiotherapy in recent guidelines.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"21 2","pages":"113-123"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/e3/jlc-2021-05-26.PMC10035685.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9736720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transarterial chemoembolization using drug-eluting bead compared with radiofrequency ablation for treatment of single small hepatocellular carcinoma: a pilot non-randomized trial.","authors":"Tae Hoon Kim,&nbsp;Na Hye Kim,&nbsp;Jin Dong Kim,&nbsp;Young Nam Kim,&nbsp;Yu Jin Kim,&nbsp;Eun Jung Kim,&nbsp;Ki Deok Yoo,&nbsp;Choong Heon Ryu,&nbsp;Ha Hun Song,&nbsp;Hyun Kim","doi":"10.17998/jlc.2021.05.20","DOIUrl":"https://doi.org/10.17998/jlc.2021.05.20","url":null,"abstract":"<p><strong>Background/aims: </strong>Surgical resection, transplantation, and radiofrequency ablation (RFA) are generally accepted as amenable treatments for small hepatocellular carcinoma (HCC). Recently drug-eluting beads (DEB) which had several treatment advantages were introduced for transarterial chemoembolization (TACE). The aim of this study was to evaluate feasibility and safety of DEB-TACE compared with RFA for the treatment of single small HCC.</p><p><strong>Methods: </strong>In this pilot non-randomized trial, we assessed retrospective data of 40 patients who underwent DEB-TACE (n=21) or RFA (n=19) for single small (≤3 centimeter in greatest dimension) HCC. The primary outcomes were tumor response and time to recurrence. The secondary outcome was treatment-related complications.</p><p><strong>Results: </strong>Complete response rate to DEB-TACE and RFA after first follow-up assessment was 90.5% and 94.7%, respectively (<i>P</i>=1.000). During mean follow-up of 87.6 months (95% confidence interval, 74.4-102), 7 patients experienced local recurrence. The 6- and 12-month cumulative local recurrence rate was 5.0% and 21.8% in DEB-TACE vs. 11.1% and 17.0% in RFA group (<i>P</i>=0.877). A total 14 distant intrahepatic recurrences were developed and 12- and 24-month cumulative distant intrahepatic recurrence rate was 20.6% and 42.7% in DEB-TACE vs. 17.2% and 36.3% in RFA group (<i>P</i>=0.844). Two patients experienced gangrenous cholecystitis after DEB-TACE requiring cholecystectomy as treatment-related adverse event.</p><p><strong>Conclusions: </strong>Tumor response and recurrence rate after single session of DEB-TACE or RFA were similar. DEB-TACE could be applied selectively in patients with a single small HCC if the other therapeutic modality is unfeasible.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"21 2","pages":"146-154"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1d/b9/jlc-2021-05-20.PMC10035690.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9736721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary multifocal cystic signet ring neuroendocrine tumor of liver: a case report.","authors":"Nalini Bansal,&nbsp;Brahmananda Satapathy","doi":"10.17998/jlc.2021.09.17","DOIUrl":"https://doi.org/10.17998/jlc.2021.09.17","url":null,"abstract":"<p><p>Primary signet ring neuroendocrine tumors of the liver are extremely rare tumors. Morphologically, they mimic signet ring cell adenocarcinomas; however, the absence of mucin by special stains and the expression of neuroendocrine markers help to diagnose these tumors. We herein report a case of a 47-year-old female who presented with multiple solid and cystic lesions in both liver lobes, which were initially suggested to be biliary cystadenocarcinoma on imaging. Liver biopsy of the lesion revealed the presence of a signet ring neoplasm with diffuse expression of synaptophysin and pan-cytokeratin. The case was subsequently diagnosed as a primary hepatic signet ring neuroendocrine tumor. The patient was offered 3 cycles of chemotherapy and is well preserved after 14 months of diagnosis. Although this is an extremely rare entity, its possibility should be considered in the differential diagnosis of neoplasms characterized by signet ring cell morphology.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"21 2","pages":"187-193"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/71/jlc-2021-09-17.PMC10035681.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9791909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case report of a patient presented with skin ulcer after treatment of lenvatinib.","authors":"Serin Cha,&nbsp;Dong Woo Kim,&nbsp;Jung Wan Choe,&nbsp;Tae Hyung Kim,&nbsp;Seung Young Kim,&nbsp;Jong Jin Hyun,&nbsp;Sung Woo Jung,&nbsp;Ja Seol Koo,&nbsp;Young Kul Jung,&nbsp;Hyung Joon Yim","doi":"10.17998/jlc.2021.09.20","DOIUrl":"https://doi.org/10.17998/jlc.2021.09.20","url":null,"abstract":"<p><p>A 60-year-old man diagnosed with unresectable hepatocellular carcinoma (HCC) presented to the hospital with pain in the perineal region. He had been taking lenvatinib every day for 2 months after he was diagnosed with HCC with metastases to the lymph node, small bowel mesentery, and retroperitoneal space. Enhanced abdominal computed tomography revealed mild elevation in intensity in the perineal subcutaneous tissue with subcutaneous emphysema. The patient was diagnosed with Common Terminology Criteria for Adverse Events grade 3, skin ulceration of stage IV with full-thickness skin loss and tissue necrosis in the muscular layer. The patient was taken off the medication with prescription of antibiotics, and after 3 weeks, the skin has fully recovered. This is the first report of an HCC patient who presented with a skin ulceration of stage IV after lenvatinib treatment. We recommend stopping the medication immediately and changing to alternative treatments with appropriate supportive care.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"21 2","pages":"194-198"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/c5/jlc-2021-09-20.PMC10035686.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9736716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}